Google
GRCE — GRACE THERAPEUTICS, INC. (Healthcare >> Biotechnology)
GRCE FAQ
What is GRCE's P/E ratio?
GRACE THERAPEUTICS, INC. (GRCE) currently trades at a P/E ratio of 39.29.
What is GRCE's ROE?
GRACE THERAPEUTICS, INC. reports a Return on Equity (ROE) of -12.57%.
What is GRCE's dividend yield?
GRACE THERAPEUTICS, INC. offers a dividend yield of 0.00%.
What is GRCE's Deepscope Quality Score?
Deepscope rates GRCE's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GRCE?
Deepscope's AI Timing Score for GRCE is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GRCE belong to?
GRACE THERAPEUTICS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.20
Price
-0.10
(-4.35%)
Day Change
|
|
|---|
GRCE, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.20 |
| PBV / Sector |
0.55 / 4.91
GREAT
|
| Earning Per Share | -0.50 |
| PE / Sector |
39.29 / 18.34
|
| PEG or PE/Growth / Sector |
0.69 / 0.61
|
| Average 1M Daily Value |
0.66 M
GREAT
|
| Average 1W Daily Value |
0.49 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:57 |
| Symbol | GRCE |
| Name | GRACE THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 15.47 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 35.59 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 103 Carnegie Center, Princeton, NJ, United States, 08540
Phone: 609 322 1602
Website: https://www.gracetx.com
Sector: Healthcare >> Biotechnology
Description: Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
